Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy.

Gordin D, Shah H, Shinjo T, St-Louis R, Qi W, Park K, Paniagua SM, Pober DM, Wu IH, Bahnam V, Brissett MJ, Tinsley LJ, Dreyfuss JM, Pan H, Dong Y, Niewczas MA, Amenta P, Sadowski T, Kannt A, Keenan HA, King GL.

Diabetes Care. 2019 Jul;42(7):1263-1273. doi: 10.2337/dc18-2585. Epub 2019 May 10.

PMID:
31076418
2.

A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.

Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS.

Nat Med. 2019 May;25(5):805-813. doi: 10.1038/s41591-019-0415-5. Epub 2019 Apr 22.

PMID:
31011203
3.

IL 6 but not TNF is linked to coronary artery calcification in patients with chronic kidney disease.

Kamińska J, Stopiński M, Mucha K, Jędrzejczak A, Gołębiowski M, Niewczas MA, Pączek L, Foroncewicz B.

Cytokine. 2019 Aug;120:9-14. doi: 10.1016/j.cyto.2019.04.002. Epub 2019 Apr 13.

PMID:
30991230
4.

Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes.

Satake E, Pezzolesi MG, Md Dom ZI, Smiles AM, Niewczas MA, Krolewski AS.

Diabetes. 2018 May;67(5):1013-1023. doi: 10.2337/db17-1207. Epub 2018 Feb 16.

5.

Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, Duffin KL, Breyer MD, Pullen N, Bonventre JV, Krolewski AS.

Kidney Int. 2018 May;93(5):1198-1206. doi: 10.1016/j.kint.2017.11.024. Epub 2018 Feb 2.

6.
7.

Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.

Qi W, Keenan HA, Li Q, Ishikado A, Kannt A, Sadowski T, Yorek MA, Wu IH, Lockhart S, Coppey LJ, Pfenninger A, Liew CW, Qiang G, Burkart AM, Hastings S, Pober D, Cahill C, Niewczas MA, Israelsen WJ, Tinsley L, Stillman IE, Amenta PS, Feener EP, Vander Heiden MG, Stanton RC, King GL.

Nat Med. 2017 Jun;23(6):753-762. doi: 10.1038/nm.4328. Epub 2017 Apr 24.

8.

Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.

Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, Galecki AT, Duffin KL, Pullen N, Breyer MD, Bonventre JV, Warram JH, Krolewski AS.

Kidney Int. 2017 Jul;92(1):258-266. doi: 10.1016/j.kint.2017.02.010. Epub 2017 Apr 7.

9.

Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease.

Niewczas MA, Mathew AV, Croall S, Byun J, Major M, Sabisetti VS, Smiles A, Bonventre JV, Pennathur S, Krolewski AS.

Diabetes Care. 2017 Mar;40(3):383-390. doi: 10.2337/dc16-0173. Epub 2017 Jan 13.

10.

Metabolomic Profiling in Individuals with a Failing Kidney Allograft.

Bassi R, Niewczas MA, Biancone L, Bussolino S, Merugumala S, Tezza S, D'Addio F, Ben Nasr M, Valderrama-Vasquez A, Usuelli V, De Zan V, El Essawy B, Venturini M, Secchi A, De Cobelli F, Lin A, Chandraker A, Fiorina P.

PLoS One. 2017 Jan 4;12(1):e0169077. doi: 10.1371/journal.pone.0169077. eCollection 2017.

11.

Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes.

Nowak N, Skupien J, Niewczas MA, Yamanouchi M, Major M, Croall S, Smiles A, Warram JH, Bonventre JV, Krolewski AS.

Kidney Int. 2016 Feb;89(2):459-67.

12.

Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes.

Pavkov ME, Weil EJ, Fufaa GD, Nelson RG, Lemley KV, Knowler WC, Niewczas MA, Krolewski AS.

Kidney Int. 2016 Jan;89(1):226-34. doi: 10.1038/ki.2015.278. Epub 2016 Jan 4.

13.

Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes.

Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA.

Kidney Int. 2015 Apr;87(4):812-9. doi: 10.1038/ki.2014.330. Epub 2014 Oct 1.

14.

Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens.

Kleffel S, Vergani A, Tezza S, Ben Nasr M, Niewczas MA, Wong S, Bassi R, D'Addio F, Schatton T, Abdi R, Atkinson M, Sayegh MH, Wen L, Wasserfall CH, O'Connor KC, Fiorina P.

Diabetes. 2015 Jan;64(1):158-71. doi: 10.2337/db13-1639. Epub 2014 Sep 3.

15.

Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria.

Skupien J, Warram JH, Niewczas MA, Gohda T, Malecki M, Mychaleckyj JC, Galecki AT, Krolewski AS.

Diabetes Care. 2014 Sep;37(9):2601-8. doi: 10.2337/dc13-1983. Epub 2014 Jun 4.

16.

Role of podocyte B7-1 in diabetic nephropathy.

Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D'Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH.

J Am Soc Nephrol. 2014 Jul;25(7):1415-29. doi: 10.1681/ASN.2013050518. Epub 2014 Mar 27.

17.

Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.

Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, Smiles A, Huang X, Walker W, Byun J, Karoly ED, Kensicki EM, Berry GT, Bonventre JV, Pennathur S, Meyer TW, Krolewski AS.

Kidney Int. 2014 May;85(5):1214-24. doi: 10.1038/ki.2013.497. Epub 2014 Jan 15.

18.

Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Krolewski AS, Gohda T, Niewczas MA.

Clin Exp Nephrol. 2014 Aug;18(4):571-83. doi: 10.1007/s10157-013-0900-y. Epub 2013 Nov 12. Review.

19.

Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes.

Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, di Pietro N, Sturma M, Novelli V, Mannino GC, Formoso G, Gervino EV, Hauser TH, Muehlschlegel JD, Niewczas MA, Krolewski AS, Biolo G, Pandolfi A, Rimm E, Sesti G, Trischitta V, Hu F, Doria A.

JAMA. 2013 Aug 28;310(8):821-8. doi: 10.1001/jama.2013.276305.

20.

Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.

Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A, Warram JH.

Diabetes Care. 2014;37(1):226-34. doi: 10.2337/dc13-0985. Epub 2013 Aug 12.

21.

Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1.

Lee JE, Gohda T, Walker WH, Skupien J, Smiles AM, Holak RR, Jeong J, McDonnell KP, Krolewski AS, Niewczas MA.

PLoS One. 2013;8(3):e58007. doi: 10.1371/journal.pone.0058007. Epub 2013 Mar 20.

22.

Transcriptome analysis of proximal tubular cells (HK-2) exposed to urines of type 1 diabetes patients at risk of early progressive renal function decline.

Wanic K, Krolewski B, Ju W, Placha G, Niewczas MA, Walker W, Warram JH, Kretzler M, Krolewski AS.

PLoS One. 2013;8(3):e57751. doi: 10.1371/journal.pone.0057751. Epub 2013 Mar 7.

23.

Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes.

Merchant ML, Niewczas MA, Ficociello LH, Lukenbill JA, Wilkey DW, Li M, Khundmiri SJ, Warram JH, Krolewski AS, Klein JB.

Kidney Int. 2013 Jun;83(6):1177-84. doi: 10.1038/ki.2013.8. Epub 2013 Mar 6.

24.

Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?

Doria A, Niewczas MA, Fiorina P.

Semin Nephrol. 2012 Sep;32(5):437-44. doi: 10.1016/j.semnephrol.2012.07.006.

25.

The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease.

Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D, Stanton R, Krolewski AS.

Kidney Int. 2012 Sep;82(5):589-97. doi: 10.1038/ki.2012.189. Epub 2012 May 23.

26.

Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes.

Gohda T, Walker WH, Wolkow P, Lee JE, Warram JH, Krolewski AS, Niewczas MA.

Am J Physiol Renal Physiol. 2012 Jul 1;303(1):F157-62. doi: 10.1152/ajprenal.00443.2011. Epub 2012 Apr 18.

27.

Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes.

Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, Mayadas TN, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2012 Mar;23(3):516-24. doi: 10.1681/ASN.2011060628. Epub 2012 Jan 19.

28.

Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.

Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2012 Mar;23(3):507-15. doi: 10.1681/ASN.2011060627. Epub 2012 Jan 19.

29.

Characterization of human invariant natural killer T cells expressing FoxP3.

Engelmann P, Farkas K, Kis J, Richman G, Zhang Z, Liew CW, Borowiec M, Niewczas MA, Jalahej H, Orbán T.

Int Immunol. 2011 Aug;23(8):473-84. doi: 10.1093/intimm/dxr040. Epub 2011 Jun 27.

PMID:
21708895
30.

Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase.

Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, Krolewski AS, Bonventre JV.

Kidney Int. 2011 Feb;79(4):464-70. doi: 10.1038/ki.2010.404. Epub 2010 Oct 27.

31.

High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.

Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS.

Diabetes Care. 2010 Jun;33(6):1337-43. doi: 10.2337/dc10-0227. Epub 2010 Mar 23.

32.

Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.

Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, Warram JH, Krolewski AS.

Clin J Am Soc Nephrol. 2009 Jan;4(1):62-70. doi: 10.2215/CJN.03010608. Epub 2008 Dec 10.

33.

Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy.

Rosolowsky ET, Niewczas MA, Ficociello LH, Perkins BA, Warram JH, Krolewski AS.

Diabetes Res Clin Pract. 2008 Nov 13;82 Suppl 1:S46-53. doi: 10.1016/j.diabres.2008.09.018. Epub 2008 Oct 11. Review.

PMID:
18849087
34.

High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.

Rosolowsky ET, Ficociello LH, Maselli NJ, Niewczas MA, Binns AL, Roshan B, Warram JH, Krolewski AS.

Clin J Am Soc Nephrol. 2008 May;3(3):706-13. doi: 10.2215/CJN.04271007. Epub 2008 Feb 13.

35.

Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics.

Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2008 Apr;19(4):789-97. doi: 10.1681/ASN.2007050556. Epub 2008 Feb 6.

Supplemental Content

Loading ...
Support Center